MX2023006677A - Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). - Google Patents

Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).

Info

Publication number
MX2023006677A
MX2023006677A MX2023006677A MX2023006677A MX2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A
Authority
MX
Mexico
Prior art keywords
macular degeneration
amd
related macular
compositions
treating dry
Prior art date
Application number
MX2023006677A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Caggiano
Susan Catalano
Mary Hamby
Nicholas Izzo
Gary Look
Gilbert Rishton
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of MX2023006677A publication Critical patent/MX2023006677A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023006677A 2020-12-11 2021-12-10 Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). MX2023006677A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (1)

Publication Number Publication Date
MX2023006677A true MX2023006677A (es) 2023-06-27

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006677A MX2023006677A (es) 2020-12-11 2021-12-10 Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).

Country Status (10)

Country Link
US (1) US20240009168A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553414A (cg-RX-API-DMAC7.html)
KR (1) KR20230118158A (cg-RX-API-DMAC7.html)
CN (1) CN116867488A (cg-RX-API-DMAC7.html)
AU (1) AU2021396380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200346A1 (cg-RX-API-DMAC7.html)
IL (1) IL303592A (cg-RX-API-DMAC7.html)
MX (1) MX2023006677A (cg-RX-API-DMAC7.html)
WO (1) WO2022125925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
ES2969373B2 (es) 2022-10-14 2025-02-06 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo
WO2025122753A2 (en) * 2023-12-08 2025-06-12 Cognition Therapeutics, Inc. Compositions and methods for the treatment of niemann-pick disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Also Published As

Publication number Publication date
KR20230118158A (ko) 2023-08-10
AU2021396380A1 (en) 2023-06-22
CA3200346A1 (en) 2022-06-16
CN116867488A (zh) 2023-10-10
EP4259129A4 (en) 2024-11-27
IL303592A (en) 2023-08-01
WO2022125925A1 (en) 2022-06-16
JP2023553414A (ja) 2023-12-21
US20240009168A1 (en) 2024-01-11
EP4259129A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
PH12020500134A1 (en) Dihydrooxadiazinones
AU2020231934A8 (en) Compounds useful in HIV therapy
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112023001792A2 (pt) Combinações para o tratamento de câncer
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
EA201791321A1 (ru) Составы ингибитора lfa-1
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
CR20250181A (es) Compuesto fungicida
BR112021020027A2 (pt) Compostos, composições e métodos
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias